Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

Sharmilan Thanendrarajan

TitleAssistant Professor
InstitutionUniversity of Arkansas for Medical Sciences
DepartmentInternal Med, College of Medicine
DivisionInternal Med Hem-Onc
Address4104 Outpatient Circle
Mail Slot # 816
Little Rock AR 72205
Phone501-526-6990
vCardDownload vCard

    Collapse Overview 
    Collapse overview
    Sharmilan Thanendrarajan, M.D., is an Assistant Professor of Medicine with the Myeloma Institute for Research and Therapy at the University of Arkansas for Medical Sciences.Dr. Thanendrarajan trained as a fellow in Hematology/Oncology at University Clinic of Bonn in Germany. He trained as a resident in Internal Medicine at University Clinic of Bonn and General Hospital of Hagen. Dr. Thanendrarajan earned his M.D. from the Medical College of Ruhr-University in Bochum, Germany. He is a member of the German Society of Internal Medicine, the German Cancer Society, the German Society for Hematology and Oncology, the European Society for Medical Oncology and the European Myeloma Network. Dr. Thanendrarajan is board certified in Germany in Internal Medicine and Hematology/Oncology. Publications: http://www.ncbi.nlm.nih.gov/pubmed/?term=thanendrarajan+sTo make an appointment with Dr. Thanendrarajan, please call 1-888-MYELOMA.


    Collapse Research Funds 
    Collapse research activities
    BRF117019     (THANENDRARAJAN, SHARMILAN)Nov 4, 2014
    GlaxoSmithKline
    BRF117019
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions. Don't see publications published under other names? Login to add alternative names.
    List All   |   Timeline
    1. Nishimura KK, Barlogie B, van Rhee F, Zangari M, Walker BA, Rosenthal A, Schinke C, Thanendrarajan S, Davies FE, Hoering A, Morgan GJ. Long-term outcomes after autologous stem cell transplantation for multiple myeloma. Blood Adv. 2020 Jan 28; 4(2):422-431. PMID: 31990333.
      View in: PubMed
    2. Boyle EM, Ashby C, Tytarenko R, Deshpande S, Wang Y, Sawyer J, Tian E, Johnson S, Rutherford MW, Wardell CP, Bauer MA, Thanendrarajan S, Schinke C, Zangari M, van Rhee F, Wang H, Rosenthal A, Hoering A, Flynt E, Thakurta A, Dumontet C, Facon T, Cairns DA, Jackson GH, Barlogie B, Davies FE, Morgan GJ, Walker BA. BRAF and DIS3 Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma. Clin Cancer Res. 2020 Jan 27. PMID: 31988198.
      View in: PubMed
    3. Sawyer JR, Tian E, Walker BA, Wardell C, Lukacs JL, Sammartino G, Bailey C, Schinke CD, Thanendrarajan S, Davies FE, Morgan GJ, Barlogie B, Zangari M, van Rhee F. An acquired high-risk chromosome instability phenotype in multiple myeloma: Jumping 1q Syndrome. Blood Cancer J. 2019 08 09; 9(8):62. PMID: 31399558.
      View in: PubMed
    4. Rasche L, Kumar M, Gershner G, Samant R, Van Hemert R, Heidemeier A, Lapa C, Bley T, Buck A, McDonald J, Hillengass J, Epstein J, Thanendrarajan S, Schinke C, van Rhee F, Zangari M, Barlogie B, Davies FE, Morgan GJ, Weinhold N. Lack of Spleen Signal on Diffusion Weighted MRI is associated with High Tumor Burden and Poor Prognosis in Multiple Myeloma: A Link to Extramedullary Hematopoiesis? Theranostics. 2019; 9(16):4756-4763. PMID: 31367255.
      View in: PubMed
    5. Mohan M, Susanibar-Adaniya S, Buros A, Crescencio JCR, Burgess MJ, Lusardi K, Davies F, Morgan G, Vanrhee F, Zangari M, Schinke C, Thanendrarajan S, Kothari A. Bacteremias following autologous stem cell transplantation for multiple myeloma: Risk factors and outcomes. Transpl Infect Dis. 2019 Apr; 21(2):e13052. PMID: 30689291.
      View in: PubMed
    6. Ashby C, Tytarenko RG, Wang Y, Weinhold N, Johnson SK, Bauer M, Wardell CP, Schinke C, Thanendrarajan S, Zangari M, van Rhee F, Davies FE, Sawyer JR, Morgan GJ, Walker BA. Poor overall survival in hyperhaploid multiple myeloma is defined by double-hit bi-allelic inactivation of TP53. Oncotarget. 2019 Jan 22; 10(7):732-737. PMID: 30774775.
      View in: PubMed
    7. Rasche L, Alapat D, Kumar M, Gershner G, McDonald J, Wardell CP, Samant R, Van Hemert R, Epstein J, Williams AF, Thanendrarajan S, Schinke C, Bauer M, Ashby C, Tytarenko RG, van Rhee F, Walker BA, Zangari M, Barlogie B, Davies FE, Morgan GJ, Weinhold N. Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma. Leukemia. 2019 07; 33(7):1713-1722. PMID: 30573775.
      View in: PubMed
    8. Mehdi SJ, Johnson SK, Epstein J, Zangari M, Qu P, Hoering A, van Rhee F, Schinke C, Thanendrarajan S, Barlogie B, Davies FE, Morgan GJ, Yaccoby S. Mesenchymal stem cells gene signature in high-risk myeloma bone marrow linked to suppression of distinct IGFBP2-expressing small adipocytes. Br J Haematol. 2019 02; 184(4):578-593. PMID: 30408155.
      View in: PubMed
    9. Atrash S, Dua I, Buros AF, Van Rhee F, Suva LJ, Thanendrarajan S, Schinke C, Davies F, Morgan G, Zangari M. FRAX is a robust predictor of baseline vertebral fractures in multiple myeloma patients. Bone. 2019 04; 121:134-138. PMID: 30244157.
      View in: PubMed
    10. Rasche L, Angtuaco EJ, Alpe TL, Gershner GH, McDonald JE, Samant RS, Kumar M, Van Hemert R, Epstein J, Deshpande S, Tytarenko R, Yaccoby S, Hillengass J, Thanendrarajan S, Schinke C, van Rhee F, Zangari M, Walker BA, Barlogie B, Morgan GJ, Davies FE, Weinhold N. The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma. Blood. 2018 07 05; 132(1):59-66. PMID: 29784643.
      View in: PubMed
    11. Morgan GJ, He J, Tytarenko R, Patel P, Stephens OW, Zhong S, Deshpande S, Bauer M, Weinhold N, Schinke C, Rasche L, Bailey M, Ali S, Ross J, Miller VA, Stephens P, Thanendrarajan S, Zangari M, van Rhee F, Mughal T, Davies FE, Walker BA. Kinase domain activation through gene rearrangement in multiple myeloma. Leukemia. 2018 11; 32(11):2435-2444. PMID: 29654269.
      View in: PubMed
    12. Davies FE, Rosenthal A, Rasche L, Petty NM, McDonald JE, Ntambi JA, Steward DM, Panozzo SB, van Rhee F, Zangari M, Schinke CD, Thanendrarajan S, Walker B, Weinhold N, Barlogie B, Hoering A, Morgan GJ. Treatment to suppression of focal lesions on positron emission tomography-computed tomography is a therapeutic goal in newly diagnosed multiple myeloma. Haematologica. 2018 06; 103(6):1047-1053. PMID: 29567784.
      View in: PubMed
    13. Schinke C, Qu P, Mehdi SJ, Hoering A, Epstein J, Johnson SK, van Rhee F, Zangari M, Thanendrarajan S, Barlogie B, Davies FE, Yaccoby S, Morgan GJ. The Pattern of Mesenchymal Stem Cell Expression Is an Independent Marker of Outcome in Multiple Myeloma. Clin Cancer Res. 2018 06 15; 24(12):2913-2919. PMID: 29563136.
      View in: PubMed
    14. Mathur P, Alapat D, Kumar M, Thanendrarajan S. Metastatic prostate cancer with bone marrow infiltration mimicking multiple myeloma. Clin Case Rep. 2018 02; 6(2):269-273. PMID: 29445461.
      View in: PubMed
    15. Mathur P, Thanendrarajan S, Paydak H, Vallurupalli S, Jambhekar K, Bhatti S, Schinke CD, Davies FE, Mehta JL. Cardiovascular complications of multiple myeloma in the elderly. Expert Rev Cardiovasc Ther. 2017 Dec; 15(12):933-943. PMID: 29164945.
      View in: PubMed
    16. Mathur P, Hollowoa B, Lala N, Thanendrarajan S, Matin A, Kothari A, Schinke C. Enterococcus raffinosus infection with atypical hemolytic uremic syndrome in a multiple myeloma patient after autologous stem cell transplant. Hematol Rep. 2017 Sep 26; 9(3):7094. PMID: 29071054.
      View in: PubMed
    17. Rasche L, Chavan SS, Stephens OW, Patel PH, Tytarenko R, Ashby C, Bauer M, Stein C, Deshpande S, Wardell C, Buzder T, Molnar G, Zangari M, van Rhee F, Thanendrarajan S, Schinke C, Epstein J, Davies FE, Walker BA, Meissner T, Barlogie B, Morgan GJ, Weinhold N. Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing. Nat Commun. 2017 08 16; 8(1):268. PMID: 28814763.
      View in: PubMed
    18. Mohan M, Buros A, Mathur P, Gokden N, Singh M, Susanibar S, Jo Kamimoto J, Hoque S, Radhakrishnan M, Matin A, Davis C, Grazziutti M, Thanendrarajan S, van Rhee F, Zangari M, Davies F, Morgan G, Epstein J, Barlogie B, Schinke C. Clinical characteristics and prognostic factors in multiple myeloma patients with light chain deposition disease. Am J Hematol. 2017 Aug; 92(8):739-745. PMID: 28383130.
      View in: PubMed
    19. Thanendrarajan S, Tian E, Qu P, Mathur P, Schinke C, van Rhee F, Zangari M, Rasche L, Weinhold N, Alapat D, Bellamy W, Ashby C, Mattox S, Epstein J, Yaccoby S, Barlogie B, Hoering A, Bauer M, Walker BA, Davies FE, Morgan GJ. The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma. Haematologica. 2017 09; 102(9):e364-e367. PMID: 28550191.
      View in: PubMed
    20. Rasche L, Angtuaco E, McDonald JE, Buros A, Stein C, Pawlyn C, Thanendrarajan S, Schinke C, Samant R, Yaccoby S, Walker BA, Epstein J, Zangari M, van Rhee F, Meissner T, Goldschmidt H, Hemminki K, Houlston R, Barlogie B, Davies FE, Morgan GJ, Weinhold N. Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma. Blood. 2017 07 06; 130(1):30-34. PMID: 28432222.
      View in: PubMed
    21. Susanibar-Adaniya S, Mathur P, Henrich Lobo R, Alapat D, Kumar M, Heuck C, Thanendrarajan S. Nasopharyngeal amyloidoma with osteolytic lesions leading to diagnosis of systemic light-chain amyloidosis. Clin Case Rep. 2017 06; 5(6):812-815. PMID: 28588817.
      View in: PubMed
    22. Mohan M, Samant RS, Yoon D, Buros AF, Branca A, Montgomery CO, Nicholas R, Suva LJ, Morello R, Thanendrarajan S, Schinke C, Yaccoby S, van Rhee F, Davies FE, Morgan GJ, Zangari M. Extensive Remineralization of Large Pelvic Lytic Lesions Following Total Therapy Treatment in Patients With Multiple Myeloma. J Bone Miner Res. 2017 Jun; 32(6):1261-1266. PMID: 28240368.
      View in: PubMed
    23. Chavan SS, He J, Tytarenko R, Deshpande S, Patel P, Bailey M, Stein CK, Stephens O, Weinhold N, Petty N, Steward D, Rasche L, Bauer M, Ashby C, Peterson E, Ali S, Ross J, Miller VA, Stephens P, Thanendrarajan S, Schinke C, Zangari M, van Rhee F, Barlogie B, Mughal TI, Davies FE, Morgan GJ, Walker BA. Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker. Blood Cancer J. 2017 02 24; 7(2):e535. PMID: 28234347.
      View in: PubMed
    24. McDonald JE, Kessler MM, Gardner MW, Buros AF, Ntambi JA, Waheed S, van Rhee F, Zangari M, Heuck CJ, Petty N, Schinke C, Thanendrarajan S, Mitchell A, Hoering A, Barlogie B, Morgan GJ, Davies FE. Assessment of Total Lesion Glycolysis by 18F FDG PET/CT Significantly Improves Prognostic Value of GEP and ISS in Myeloma. Clin Cancer Res. 2017 04 15; 23(8):1981-1987. PMID: 27698001.
      View in: PubMed
    25. Jethava Y, Mitchell A, Zangari M, Waheed S, Schinke C, Thanendrarajan S, Sawyer J, Alapat D, Tian E, Stein C, Khan R, Heuck CJ, Petty N, Avery D, Steward D, Smith R, Bailey C, Epstein J, Yaccoby S, Hoering A, Crowley J, Morgan G, Barlogie B, van Rhee F. Dose-dense and less dose-intense total therapy 5 for gene expression profiling-defined high-risk multiple myeloma. Blood Cancer J. 2016 09 16; 6:e471. PMID: 27635734.
      View in: PubMed
    26. Weinhold N, Ashby C, Rasche L, Chavan SS, Stein C, Stephens OW, Tytarenko R, Bauer MA, Meissner T, Deshpande S, Patel PH, Buzder T, Molnar G, Peterson EA, van Rhee F, Zangari M, Thanendrarajan S, Schinke C, Tian E, Epstein J, Barlogie B, Davies FE, Heuck CJ, Walker BA, Morgan GJ. Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma. Blood. 2016 09 29; 128(13):1735-44. PMID: 27516441.
      View in: PubMed
    27. Jethava Y, Mitchell A, Zangari M, Waheed S, Schinke C, Thanendrarajan S, Sawyer J, Alapat D, Tian E, Stein C, Khan R, Heuck CJ, Petty N, Avery D, Steward D, Smith R, Bailey C, Epstein J, Yaccoby S, Hoering A, Crowley J, Morgan G, Barlogie B, van Rhee F. Dose-dense and less dose-intense Total Therapy 5 for gene expression profiling-defined high-risk multiple myeloma. Blood Cancer J. 2016 07 29; 6(7):e453. PMID: 27471869.
      View in: PubMed
    28. Thanendrarajan S, Davies FE, Morgan GJ, Schinke C, Mathur P, Heuck CJ, Zangari M, Epstein J, Yaccoby S, Weinhold N, Barlogie B, van Rhee F. Monoclonal antibody therapy in multiple myeloma: where do we stand and where are we going? Immunotherapy. 2016; 8(3):367-84. PMID: 26888183.
      View in: PubMed
    29. Weinhold N, Heuck CJ, Rosenthal A, Thanendrarajan S, Stein CK, Van Rhee F, Zangari M, Hoering A, Tian E, Davies FE, Barlogie B, Morgan GJ. Clinical value of molecular subtyping multiple myeloma using gene expression profiling. Leukemia. 2016 Feb; 30(2):423-30. PMID: 26526987.
      View in: PubMed
    30. Mathur P, Paydak H, Thanendrarajan S, van Rhee F. Atrial Fibrillation in Hematologic Malignancies, Especially After Autologous Hematopoietic Stem Cell Transplantation: Review of Risk Factors, Current Management, and Future Directions. Clin Lymphoma Myeloma Leuk. 2016 Feb; 16(2):70-5. PMID: 26776085.
      View in: PubMed
    31. Kebir S, Kuchelmeister K, Niehusmann P, Nelles M, Kim Y, Thanendrarajan S, Schäfer N, Stuplich M, Mack F, Scheffler B, Urbach H, Glas M, Herrlinger U. Intravascular CNS lymphoma: Successful therapy using high-dose methotrexate-based polychemotherapy. Exp Hematol Oncol. 2012 Dec 05; 1(1):37. PMID: 23217063.
      View in: PubMed
    32. Thanendrarajan S, Kim Y, Schmidt-Wolf I. New adoptive immunotherapy strategies for solid tumours with CIK cells. Expert Opin Biol Ther. 2012 May; 12(5):565-72. PMID: 22444075.
      View in: PubMed
    33. Stuplich M, Mayer K, Kim Y, Thanendrarajan S, Simon M, Schäfer N, Glas M, Schmidt-Wolf IG, Herrlinger U. Richter syndrome and brain involvement: low-grade lymphoma relapsing as cerebral high-grade lymphoma. Acta Haematol. 2012; 127(2):93-5. PMID: 22156510.
      View in: PubMed
    34. Thanendrarajan S, Kim Y, Schmidt-Wolf IG. Understanding and Targeting the Wnt/ß-Catenin Signaling Pathway in Chronic Leukemia. Leuk Res Treatment. 2011; 2011:329572. PMID: 23213540.
      View in: PubMed
    35. Kim Y, Thanendrarajan S, Schmidt-Wolf IG. Wnt/ß-catenin: a new therapeutic approach to acute myeloid leukemia. Leuk Res Treatment. 2011; 2011:428960. PMID: 23213543.
      View in: PubMed
    36. Schäfer N, Tichy J, Thanendrarajan S, Kim Y, Stuplich M, Mack F, Rieger J, Simon M, Scheffler B, Boström J, Steinbach JP, Herrlinger U, Glas M. Ifosfamide, carboplatin and etoposide in recurrent malignant glioma. Oncology. 2011; 80(5-6):330-2. PMID: 21791942.
      View in: PubMed
    37. Thanendrarajan S, Nowak M, Abken H, Schmidt-Wolf IG. Combining cytokine-induced killer cells with vaccination in cancer immunotherapy: more than one plus one? Leuk Res. 2011 Sep; 35(9):1136-42. PMID: 21652069.
      View in: PubMed
    Thanendrarajan's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _